Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Radiotherapy - what's new? Q & A

Future Horizons in Lung Cancer

Sorry, this item is currently unavailable.

Published: 5 Oct 2016

Views: 1701

Rating:

Save

Dr David Landau and Prof Corinne Favire-Finn

Dr Landau and Prof Favire-Finn answer questions on their sessions discussing advances in radiotherapy, at the Future Horizons in Lung Cancer meeting.

Related Videos

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr...

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

TROP2 expression measured by QCS is a promising predictor of clinical outcomes...

Dr Marina Garassino - University of Chicago, Chicago, USA

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

TARGIT trial in intraoperative radiotherapy

Dr Gourav Gupta - Balco Medical Center, Raipur, India

TARGIT trial in intraoperative radiotherapy ( Dr Gourav Gupta - Balco Medical Center, Raipur, India )

Choosing Wisely for young women with breast cancer: Radiotherapy

Dr Tabassum Wadasadawala - Tata Memorial Hospital, Mumbai, India

Choosing Wisely for young women with breast cancer: Radiotherapy ( Dr Tabassum Wadasadawala - Tata Memorial Hospital, Mumbai, India )

Changing landscape of breast cancer diagnosis

Dr Nisha Vishnu - Fortis Healthcare & MACs Clinic, Bangalore, India

Changing landscape of breast cancer diagnosis ( Dr Nisha Vishnu - Fortis Healthcare & MACs Clinic, Bangalore, India )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Research highlights in lung cancer

Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA

Research highlights in lung cancer ( Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA )

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA

Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

More from ecancer